案例库 · 产品与设计 · 产品决策 · 2017–2018
这条还没译成中文，下面是英文原文。
Dexcom's G6 made glucose monitoring continuous and fingerstick-free
A skin sensor streams glucose every few minutes to a phone; the G6's factory calibration removed fingersticks, and trials showed HbA1c falling 0.6% more.
Dexcom
那一手
Fingerstick meters give point samples, so the dangerous swings between tests go unseen, especially for people with type 1 diabetes who use injections rather than pumps.
Dexcom's G6 puts a small sensor under the skin that measures interstitial glucose every few minutes and streams trends and alarms. Authorized by the FDA in March 2018 (De Novo DEN170088), it was the first real-time integrated CGM with factory calibration — no fingersticks for calibration or treatment decisions — and a 10-day wear.
The DIAMOND randomized trial (158 adults, JAMA 2017) found CGM lowered HbA1c by 1.0 percent versus 0.4 percent for injection users at 24 weeks, with 93 percent of participants wearing the sensor six days a week or more.
为什么管用
- Continuous trend data reveal patterns a snapshot cannot.
- Alarms turn dangerous lows into preventable events.
- Factory calibration removed the biggest adoption barrier.
- Longer wear and smartphone streaming cut the daily burden.
可以搬走什么
A monitoring tool wins when it removes its own maintenance: every calibration, charge and swap is friction that a point-in-time product never had to carry.
后来呢
The G6's integrated-CGM designation let it drive automated insulin-dosing systems, and the smaller G7 followed; CGM moved from specialty to standard of care for insulin users.
资料来源
- FDA De Novo DEN170088 — Dexcom G6 Continuous Glucose Monitoring System
- Dexcom G6 — Does the system require calibrations?
- Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections (DIAMOND, JAMA 2017)
发现哪里写错了？告诉我们。